NO970783L - Procedure for preventing endometrial cancer - Google Patents

Procedure for preventing endometrial cancer

Info

Publication number
NO970783L
NO970783L NO970783A NO970783A NO970783L NO 970783 L NO970783 L NO 970783L NO 970783 A NO970783 A NO 970783A NO 970783 A NO970783 A NO 970783A NO 970783 L NO970783 L NO 970783L
Authority
NO
Norway
Prior art keywords
endometrial cancer
procedure
preventing
preventing endometrial
hexamethylenimino
Prior art date
Application number
NO970783A
Other languages
Norwegian (no)
Other versions
NO970783D0 (en
Inventor
Susan Margaret Boss
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO970783D0 publication Critical patent/NO970783D0/en
Publication of NO970783L publication Critical patent/NO970783L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Fremgangsmåte for å hindre endometrialkreft ^-^^...JX&i^i¿^ (D i -(Ci-C,.al)cyl) (a) 0 II -c-xr (b) Det er beskrevet en fremgangsmåte for inhibering av endometrialkreft som iimbefatter at det til et menneske som har behov for dette administreres en effektiv mengde av en forbindelse av formel (I), hvor R^ og r3 uavhengig av hverandre er hydrogen, -CH3, (a) eller (b), hvor Ar er evenUielt substituert fenyl; r2 er valgt fra gruppen bestående av pyrrolidin, heksametylenimino eller piperidino; eller et farmaseytisk akseptabelt salt eller solvat derav.Procedure for Preventing Endometrial Cancer ^ - ^^ ... JX & i ^ i¿ ^ (D i - (Ci-C, al) cyl) (a) 0 II of endometrial cancer which includes administering to a human in need thereof an effective amount of a compound of formula (I) wherein R 1 and R 3 are independently hydrogen, -CH 3 Ar is optionally substituted phenyl; r 2 is selected from the group consisting of pyrrolidine, hexamethylenimino or piperidino; or a pharmaceutically acceptable salt or solvate thereof.

NO970783A 1994-08-22 1997-02-20 Procedure for preventing endometrial cancer NO970783L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29385394A 1994-08-22 1994-08-22
PCT/US1995/010651 WO1996005833A1 (en) 1994-08-22 1995-08-21 Methods of inhibiting endometrial cancer

Publications (2)

Publication Number Publication Date
NO970783D0 NO970783D0 (en) 1997-02-20
NO970783L true NO970783L (en) 1997-02-20

Family

ID=23130867

Family Applications (1)

Application Number Title Priority Date Filing Date
NO970783A NO970783L (en) 1994-08-22 1997-02-20 Procedure for preventing endometrial cancer

Country Status (17)

Country Link
EP (1) EP0777476A4 (en)
JP (1) JPH10504824A (en)
KR (1) KR970705387A (en)
AU (1) AU688112B2 (en)
CA (1) CA2198119A1 (en)
CZ (1) CZ51897A3 (en)
FI (1) FI970717L (en)
HU (1) HUT76890A (en)
IL (1) IL115022A (en)
MX (1) MX9701327A (en)
MY (1) MY113757A (en)
NO (1) NO970783L (en)
NZ (1) NZ292017A (en)
RU (1) RU2161964C2 (en)
TW (1) TW404834B (en)
WO (1) WO1996005833A1 (en)
ZA (1) ZA956994B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856340A (en) * 1995-02-28 1999-01-05 Eli Lilly And Company Method of treating estrogen dependent cancers
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
KR20160066490A (en) * 2014-12-02 2016-06-10 주식회사 씨앤드씨신약연구소 Heterocyclic derivatives and use thereof
CN115825414B (en) * 2023-01-09 2023-04-25 中国医学科学院北京协和医院 Blood or urine metabolic marker and application thereof in endometrial cancer early screening

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
JP3157882B2 (en) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 New benzothiophene derivatives
US5482949A (en) * 1993-03-19 1996-01-09 Eli Lilly And Company Sulfonate derivatives of 3-aroylbenzo[b]thiophenes
JPH08512197A (en) * 1993-04-07 1996-12-24 リガンド・ファーマシューティカルズ・インコーポレーテッド Method for screening receptor agonist
ZA948025B (en) * 1993-10-15 1996-04-15 Lilly Co Eli Methods for treating resistant neoplasms
ZA956988B (en) * 1994-08-22 1997-02-21 Lilly Co Eli Methods of inhibiting primary endometrial hyperplasia.
US5843964A (en) * 1994-09-22 1998-12-01 Eli Lilly And Company Methods of inhibiting endometrial mitoses

Also Published As

Publication number Publication date
EP0777476A4 (en) 1999-06-23
MX9701327A (en) 1997-05-31
KR970705387A (en) 1997-10-09
CA2198119A1 (en) 1996-02-29
HUT76890A (en) 1997-12-29
FI970717A7 (en) 1997-02-20
FI970717A0 (en) 1997-02-20
EP0777476A1 (en) 1997-06-11
FI970717L (en) 1997-02-20
TW404834B (en) 2000-09-11
AU3370095A (en) 1996-03-14
ZA956994B (en) 1997-02-21
AU688112B2 (en) 1998-03-05
RU2161964C2 (en) 2001-01-20
IL115022A0 (en) 1998-06-15
NZ292017A (en) 2000-07-28
NO970783D0 (en) 1997-02-20
CZ51897A3 (en) 1997-06-11
IL115022A (en) 2000-07-31
MY113757A (en) 2002-05-31
WO1996005833A1 (en) 1996-02-29
JPH10504824A (en) 1998-05-12

Similar Documents

Publication Publication Date Title
NO971520L (en) Method of inhibiting conditions associated with neuropeptide Y
NO944928L (en) Methods for inhibiting Alzheimer's disease
NO973635L (en) Method of inhibiting cell-cell adhesion
UA26930C2 (en) MEANS FOR DEFINITION OF ECHOMETRIOSIS
DK0659417T3 (en) Methods for inhibiting dysfunctional uterine bleeding
NO944925D0 (en) Steps to increase libido in post-menopausal women
NO944933L (en) Procedure for inhibiting disease states of the breast
NO970786L (en) Procedure for inhibiting bone degradation
NO944924L (en) Procedures for inhibiting Turner's syndrome
NO944917D0 (en) Use of 2-phenyl-3-aroylthiophenes for inhibition of ovarian dysgenesis, delayed puberty or sexual infantilism
NO975580L (en) Method of inhibiting melanoma
NO970783L (en) Procedure for preventing endometrial cancer
NO973367L (en) Method of inhibiting environmental estrogen
NO973609L (en) Method of inhibiting the effects of IL-6
NO981578L (en) Method of inhibiting plasminogen activator inhibitor I
NO971794L (en) Method of inhibiting states associated with bradykinin
NO971029L (en) Methods for inhibiting endometrial metoses
NO970785L (en) Procedures for bone healing and fracture repair
NO973103L (en) Method for inhibiting growth hormone effects
NO970787L (en) Procedure for inhibition of primary endometrial hyperplasia
NO983452L (en) Procedures for Inhibiting Musculoaponeurotic Fibromatosis (Desmoid Tumors)
NO944909L (en) Methods for inhibiting male infertility
NO983451L (en) Procedure for inhibiting colon tumors
NO973470L (en) Procedure for reducing serum calcium levels

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application